We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Diagnostic Panel Used for Pediatric Musculoskeletal Infections

By LabMedica International staff writers
Posted on 31 Jul 2019
The findings from a retrospective analysis suggested that the use of a rapid musculoskeletal diagnostic panel, or MDP, could have shortened the time it took to identify the cause of infection, provide appropriate antibiotics and reduce the length of stay for children in hospital.

The MDP, which was recently validated in another study, combined three separate tests: the Xpert MRSA/Staphylococcus aureus skin and soft tissue infection (SA SSTI) assay, a polymerase chain reaction (PCR) assays for ermA, ermB and ermC genes to determine clindamycin resistance; and a Kingella kingae PCR assay to identify the rtxA gene. More...
Results from the Xpert MRSA/SA SSTI assay were available within three hours, and results for the PCR assays were available by 1400 hours the following calendar day.

Scientists at the Children’s Hospital Colorado (Aurora, CO, USA) included in a study 53 children aged six months to 18 years who were admitted to the hospital with symptoms persisting for less than two weeks, had bone or joint specimens collected and were administered antibiotic therapy, excluding perioperative antibiotics. The investigators identified pathogens in 69.8% of patients (37/53) who underwent standard culturing techniques and in 13 patients (16%) who had a blood culture performed. The most commonly identified pathogen was S. aureus (47.2%), and methicillin-resistant S. aureus (MRSA) was identified in 16% of these patients. Two patients had clindamycin-resistant S. aureus, and one patient had a K. kingae infection.

The MDP identified most children with culture-confirmed S. aureus infection (88%), with three patients having MRSA. When cultured, all three patients were confirmed to have MRSA. Although the MDP identified three isolates as clindamycin resistant, culture showed that one of these isolates was clindamycin susceptible. The results showed that MDP would have saved seven hours to pathogen identification (45.6 hours; interquartile range [IQR] = 23-62) compared with standard microbiology culture techniques (52.5 hours; IQR = 36.1-65.6). Additionally, use of the MDP would have improved the time to definitive antibiotic therapy by nearly 22 hours and reduced the hospital length of stay by a median of 26.4 hours.

The authors noted that cost is an important factor when considering a new diagnostic tool like the MDA. Theoretically, the decrease in length of stay would justify its expense. Justin B. Searns, MD, a hospitalist and first author of the study, said, “No approved rapid diagnostic platforms currently exist for bone and joint specimens from pediatric patients with acute musculoskeletal infection.” The study was published on June 13, 2019, in the Journal of The Pediatric Infectious Disease Society.

Related Links:
Children’s Hospital Colorado


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.